User:Papillonderecherche/sandbox

In 2011 and 2012, there was a shortage of Adderall, particularly generic versions, in U.S. pharmacies. The shortage was caused by the Drug Enforcement Administration's annual limits on the manufacture of controlled substances. Drug manufacturers apply to the DEA to make amphetamine-based medications. Once the DEA approves a manufacturer's application and gives it a quota, it can apply that quota any way it wants. For example, it can decide to formulate its controlled substances as brand-name Adderall rather than generic amphetamine salts. The Food and Drug Administration, which maintains a | list of drug shortages, stated that the DEA's Adderall quotas were too strict. The DEA disagreed, arguing that drug manufacturers had caused the shortage by applying their quotas toward more lucrative kinds of amphetamine-based medications.